Utility of ctDNA for Response Assessment of Solid Tumors Treated with Personalized Cancer Immunotherapy
2:20 pm - Wednesday 4th February 2026
- Demonstrating how ctDNA identifies molecular response and tracks response duration where MRI-based RECIST lacks clarity
- Leveraging ctDNA alongside imaging to enable earlier and more accurate detection of therapeutic benefit in second-line advanced HCC
- Using ctDNA-guided monitoring as an exploratory endpoint to inform trial design, optimize treatment strategies, and lay the groundwork for broader regulatory acceptance
